Generate Biomedicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for Generate Biomedicines (GENB).

Price Target Range — 4 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$26Upside to Avg. PT+98.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$30
Sep 8, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$30
Aug 28, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$25→$30
May 14, 2026	Morgan Stanley	Sean Laaman	PT Raise	Overweight	$20→$22
May 8, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$16→$25
Apr 13, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Initiate	Buy	$16
Mar 24, 2026	Goldman Sachs	Salveen Richter	Initiate	Buy	$26
Mar 24, 2026	Morgan Stanley	Sean Laaman	Initiate	Overweight	$20
Mar 24, 2026	Piper Sandler	Edward Tenthoff	Initiate	Overweight	$24
Mar 24, 2026	Cantor Fitzgerald	Eric Schmidt	Initiate	Overweight	—
Mar 24, 2026	Guggenheim	Seamus Fernandez	Initiate	Buy	$30

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB) with a Buy and maintains $30 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB) with a Buy and maintains $30 price target.

Benzinga Newsdesk

Ulta Beauty To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday

Wall Street analysts updated ratings for top names. Workday target raised, Ulta Beauty & Genasys targets lowered. See how others view these stocks.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $25 to $30.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Generate Biomedicines, Raises Price Target to $22

Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweight and raises the price target from $20 to $22.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $25

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $16 to $25.

Benzinga Newsdesk

Generate Biomedicines Inc

Generate Biomedicines Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

Ulta Beauty To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday

PRO
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30

PRO
Morgan Stanley Maintains Overweight on Generate Biomedicines, Raises Price Target to $22

PRO
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $25

People Also Watch

People Also Watch

Generate Biomedicines Inc

Generate Biomedicines Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

PROHC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

Ulta Beauty To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday

PROHC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30

PROMorgan Stanley Maintains Overweight on Generate Biomedicines, Raises Price Target to $22

PROHC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $25

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30

PRO
Morgan Stanley Maintains Overweight on Generate Biomedicines, Raises Price Target to $22

PRO
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $25